- Original article
- Open Access
High-intensity circuit weight training versus aerobic training in patients with nonalcoholic fatty liver disease
Bulletin of Faculty of Physical Therapy volume 20, pages181–192(2015)
Nonalcoholic fatty liver disease (NAFLD) has become one of the most common causes of liver disease worldwide and has been recognized as a major health burden. To date, no evidence-based therapy has proven to be effective for NAFLD, except for exercise and dietary interventions. The unsuitability of weight-oriented aerobic training for obese people with NAFLD because of the difficulty in maintaining weight loss necessitates the development of alternative strategies such as resistance training.
The aim of the study was to evaluate the effect of high-intensity circuit weight training (CWT) compared with aerobic training in NAFLD patients.
Materials and methods
A randomized controlled trial enrolling 32 NAFLD patients of both sexes (15 men and 17 women) with ages ranging from 30 to 55 years without secondary liver disease (e.g. without hepatitis B virus, hepatitis C virus, or alcohol consumption) was conducted. Patients were randomly allocated either to CWT or to aerobic exercise training, three times weekly, for 3 months. Anthropometrics, lipid profile, liver enzymes, and liver steatosis were assessed. Steatosis was quantified with the hepatorenal-ultrasound index (HRI) representing the ratio between the brightness level of the liver and the right kidney.
All baseline characteristics were similar for the two treatment groups with respect to demographics, anthropometrics, lipid profile, liver enzymes, and liver steatosis on imaging. HRI score was significantly reduced in the CWT group as compared with the aerobic exercise training group (−0.38 ± 0.37 vs. −0.17 ± 0.28, P = 0.017), representing an 18 versus 8.54% relative reduction from baseline in the two groups, respectively. CWT also improved body composition, most importantly waist circumference, which was positively correlated with the change in HRI (r = 0.645 and P = 0.009).
This randomized controlled trial demonstrated a significant reduction in steatosis, as assessed by HRI, after 3 months of CWT accompanied by favorable anthropometric, lipid profile, and liver enzyme changes. CWT may serve as a complement to the treatment of NAFLD.
Mavrogiannaki AN, Migdalis IN. Nonalcoholic fatty liver disease, diabetes mellitus and cardiovascular disease: newer data. Int J Endocrinol 2013; 2013:450639.
Sanyal AJ, Brunt EM, Kleiner DE. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology 2011; 54:344–353.
Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol 2013; 10:330–344.
Vanni E, Bugianesi E, Kotronen A. From the metabolic syndrome to NAFLD or vice versa? Dig Liver Dis 2010; 42:320–330.
Loria P, Carulli L, Bertolotti M, Lonardo A. Endocrine and liver interaction: the role of endocrine pathways in NASH. Nat Rev Gastroenterol Hepatol 2009; 6:236–247.
Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011; 34:274–285.
Kubik JF, Gill RS, Laffin M. The impact of bariatric surgery on psychological health. J Obes 2013; 2013:837989.
Fontaine KR, Redden DT, Wang C. Years of life lost due to obesity. JAMA 2003; 289:187–193.
Kaplan MS, Huguet N, Newsom JT. Prevalence and correlates of overweight and obesity among older adults: findings from the Canadian National Population Health Survey. J Gerontol A Biol Sci Med Sci 2003; 58:1018–1030.
Bechmann LP, Hannivoort RA, Gerken G. The interaction of hepatic lipid and glucose metabolism in liver diseases. J Hepatol 2012; 56:952–964.
Williams CD, Stengel J, Asike MI. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011; 140:124–131.
Bellentani S, Saccoccio G, Masutti F. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 2000; 132:112–117.
Silverman JF, O’Brien KF, Long S. Liver pathology in morbidly obese patients with and without diabetes. Am J Gastroenterol 1990; 85: 1349–1355.
Hsiao TJ, Chen JC, Wang JD. Insulin resistance and ferritin as major determinants of nonalcoholic fatty liver disease in apparently healthy obese patients. Int J Obes Relat MetabDisord 2004; 28:167–172.
Marin P, Andersson B, Ottosson M. The morphology and metabolism of intraabdominal adipose tissue in men. Metabolism 1992; 41:1242–1248.
Stefan N, Kantartzis K, Machann J. Identification and characterization of metabolically benign obesity in humans. Arch Intern Med 2008; 168: 1609–1616.
Stefan N, Haring HU. The metabolically benign and malignant fatty liver. Diabetes 2011; 60:2011–2017.
Harrison SA, Day CP. Benefits of lifestyle modification in NAFLD. Gut 2007; 56:1760–1709.
Kraemer WJ, Ratamess NA. Fundamentals of resistance training: progression and exercise prescription. Med Sci Sports Exerc 2004; 36:674–688.
Johnson NA, George J. Fitness versus fatness: moving beyond weight loss in nonalcoholic fatty liver disease. Hepatology 2010; 52:370–381.
Newton JL, Jones DE, Henderson E. Fatigue in non-alcoholic fatty liver disease (NAFLD) is significant and associates with inactivity and excessive daytime sleepiness but not with liver disease severity or insulin resistance. Gut 2008; 57:807–813.
Frith J, Day CP, Robinson L. Potential strategies to improve uptake of exercise interventions in non-alcoholic fatty liver disease. J Hepatol 2010; 52:112–116.
Farrell GC, Chitturi S, Lau GK. Guidelines for the assessment and management of non-alcoholic fatty liver disease in the Asia-Pacific region: executive summary. J Gastroenterol Hepatol 2007; 22:775–777.
Welkowitz J, Ewen RB, Cohen J. Introductory statistics for the behavioral sciences. 3rd ed. San Diego, CA: Harcourt Brace Jovanovich; 1982.
Strychar I. Diet in the management of weight loss. Can Med Assoc J 2006; 174:56–63.
Nielsen SJ, Popkin BM. Changes in beverage intake between 1977 and 2001. Am J Prev Med 2004; 27:205–210.
Gore R Diffuse liver disease. In: Gore R, Levine M, Laufer I editors. Textbook of gastrointestinal radiology. Philadelphia: Saunders; 1994. 1968–2017.
Webb M, Yeshua H, Zelber-Sagi S. Diagnostic value of a computerized hepatorenal index for sonographic quantification of liver steatosis. Am J Roentgenol 2009; 192:909–914.
Franklin BA. ed. American college of sports medicine: guidelines for exercises testing and prescription. 7th ed. Baltimore, MD: Lippincott Williams & Wilkins; 2006. 220–223.
Yavari A, Najafipoor F, Aliasgarzadeh A. Effect of aerobic exercise, resistance training or combined training on glycaemic control and cardiovascular risk factors in patients with type 2 diabetes. Biol Sport 2012; 29:135–143.
Karvonen MJ, Kentala E, Mustalo O. The effects of training on heat rate; a longitudinal study. Ann Med Exp Biol Fenn. 1957; 35: 307–315.
Suzuki A, Lindor K, Saver J St. Effect of changes on body weight and lifestyle in nonalcoholic fatty liver disease. J Hepatol 2005; 43:1060–1066.
Johnson NA, Sachinwalla T, Walton DW. Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss. Hepatology 2009; 50:1105–1112.
Sullivan S, Kirk EP, Mittendorfer B. Randomized trial of exercise effect on intrahepatic triglyceride content and lipid kinetics in nonalcoholic fatty liver disease. Hepatology 2012; 55: 1738–1745.
George A, Bauman A, Johnston A. Independent effects of physical activity in patients with nonalcoholic fatty liver disease. Hepatology 2009; 50: 68–76.
Zelber-Sagi S, Nitzan-Kaluski D, Goldsmith R. Role of leisure-time physical activity in nonalcoholic fatty liver disease: a population-based study. Hepatology 2008; 48:1791–1798.
Sreenivasa Baba C, Alexander G, Kalyani B. Effect of exercise and dietary modification on serum aminotransferase levels in patients with nonalcoholic steatohepatitis. J Gastroenterol Hepatol 2006; 21:191–198.
Williams MA, Haskell WL, Ades PA. Resistance exercise in individuals with and without cardiovascular disease: 2007 update: a scientific statement from the American Heart Association Council on Clinical Cardiology and Council on Nutrition, Physical Activity, and Metabolism. Circulation 2007; 116:572–584.
Ibañez J, Izquierdo M, Argüelles I. Twice-weekly progressive resistance training decreases abdominal fat and improves insulin sensitivity in older men with type 2 diabetes. Diab Care 2005; 28:662–667.
Hallsworth K, Fattakhova G, Hollingsworth KG. Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss. Gut 2011; 60:1278–1283.
Bacchi E, Negri C, Targher G. Both resistance training and aerobic training reduce hepatic fat content in type 2 diabetic subjects with nonalcoholic fatty liver disease (the RAED2 Randomized Trial). Hepatology 2013; 58: 1287–1295.
Castaneda C, Layne JE, Munoz-Orians L. A randomized controlled trial of resistance exercise training to improve glycemic control in older adults with type 2 diabetes. Diabetes Care 2002; 25:2335–2341.
Hameed UA, Manzar D, Raza S. Resistance training leads to clinically meaningful improvements in control of glycemia and muscular strength in untrained middle-aged patients with type 2 diabetes mellitus. N Am J Med Sci 2012; 4:336–343.
Kelley GA, Kelley KS. Impact of progressive resistance training on lipids and lipoproteins in adults: a meta-analysis of randomized controlled trials. Prev Med 2009; 48:9–19.
Speliotes EK, Massaro JM, Hoffmann U. Fatty liver is associated with dyslipidemia and dysglycemia independent of visceral fat: the Framingham Heart Study. Hepatology 2010; 51:1979–1987.
Kim LJ, Nalls MA, Eiriksdottir G. Associations of visceral and liver fat with the metabolic syndrome across the spectrum of obesity: the AGESReykjavik study. Obesity (Silver Spring) 2011; 19: 1265–1271.
Simonen P, Kotronen A, Hallikainen M. Cholesterol synthesis is increased and absorption decreased in non-alcoholic fatty liver disease independent of obesity. J Hepatol 2011; 54:153–159.
Hoenig MR, Sellke FW. Insulin resistance is associated with increased cholesterol synthesis, decreased cholesterol absorption and enhanced lipid response to statin therapy. Atherosclerosis 2010; 211:260–265.
Brooks N, Layne JE, Gordon PL. Strength training improves muscle quality and insulin sensitivity in Hispanic older adults with type 2 diabetes. Int J Med Sci 2007; 4:19–27.
Vissers D, Verrijken A, Mertens I, et al. Effect of long-term whole body vibration training on visceral adipose tissue: a preliminary report. Obes Facts. 2010; 3:93–100.
So R, Eto M, Tsujimoto T. Acceleration training for improving physical fitness and weight loss in obese women. Obes Res Clin Pract 2014; 8:e238–e248.
Jensen J, Rustad PI, Kolnes AJ. The role of skeletal muscle glycogen breakdown for regulation of insulin sensitivity by exercise. Front Physiol 2011; 2:112.
Hallsworth K, Fattakhova G, Hollingsworth KG, et al. Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss. Gut 2011; 60: 1278–1283.
Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology 2010; 51:679–689.
Holten MK, Zacho M, Gaster M. Strength training increases insulin-mediated glucose uptake, GLUT4 content, and insulin signaling in skeletal muscle in patients with type 2 diabetes. Diabetes 2004; 53:294–305.
Di Loreto C, Ranchelli A, Lucidi P, et al. Effects of whole-body vibration exercise on the endocrine system of healthy men. J Endocrinol Invest 2004; 27:323–327.
About this article
Cite this article
Elsisia, H.F., Aneisb, Y.M. High-intensity circuit weight training versus aerobic training in patients with nonalcoholic fatty liver disease. Bull Fac Phys Ther 20, 181–192 (2015). https://doi.org/10.4103/1110-6611.174717
- aerobic exercise
- circuit weight training
- liver steatosis